Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Silver Trust (SLV) vs GeneDx Holdings Corp (WGS) Price & Performance

iShares Silver TrustTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

iShares Silver Trust vs GeneDx Holdings Corp — how do they compare? iShares Silver Trust trades at $54.05, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). Which is the better fit depends on your goals.

SLVWGS
52-Week High
$105.57$167.51
52-Week Low
$33.32$34.51
Market Cap
$1.80B
Sector
Technology
Enterprise Value
$1.80B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Silver Trust

SLV, the iShares Silver Trust ETF, trades at $53.08, up 4.53% on the day, amid a broader precious metals rebound. Technical indicators are predominantly bearish, with moving averages signaling sell pressure, though short-term RSI suggests potential oversold conditions. Recent news highlights silver's sensitivity to interest rate expectations and geopolitical tensions, with supply deficits and industrial demand providing fundamental support. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver.

The outlook for SLV hinges on macroeconomic factors, including Fed policy and silver's dual role as a monetary and industrial metal. Risks include persistent rate hikes and dollar strength, but long-term demand drivers offer appreciation potential. Investors should weigh silver's volatility against its hedge attributes.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.

Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.

Returns comparison

Trailing returns across standard periods

About iShares Silver Trust

The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.

Read more on SLV

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS